Shares of GenMark Diagnostics Inc. (GNMK) are rising over 13% in pre-market today, after the company announced submission of Emergency Use Authorization or EUA to the U.S. Food and Drug Administration (FDA) for its ePlex SARS-CoV-2 Test.
from RTT - Before the Bell https://ift.tt/3cRTPsk
via IFTTT
No comments:
Post a Comment